Remove 2018 Remove Biopharma Remove Safety Remove Specialization
article thumbnail

Medicinal cannabis: the route to good manufacturing practice registration

European Pharmaceutical Review

After the substance became legal in the UK in 2018, pharmaceutical companies have faced numerous obstacles to attain a fairer position in the industry. How do you see the evolution of cannabis-based medicines, particularly when it comes to the ‘specials’ or fully licensed drug routes? He founded Celadon in 2018.

Medicine 128
article thumbnail

Mainland China’s regulatory evolution brings greater access to novel drugs

Clarivate

In parallel, the CDE also established a special channel to facilitate these approvals. Despite the availability of multiple DMTs in the Western markets, there was a dearth of DMTs in Mainland China before 2018. 2] Opinion on the list of new drugs marketed overseas urgently needed in China , August 2018. [3]

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

For rare disease patients in Mainland China, hope of greater access to treatment

Clarivate

6] [7] However, in May 2018, the National Health Commission of China (NHC), together with four other national agencies, formulated China’s First List of Rare Diseases (CRDL) to provide a foundation for policymaking around rare disease treatments. 2018; 40:432-434. (in Source: Clarivate analysis. 10] [11] [12]. 10] [11] [12].

article thumbnail

Alpha TAU Killing Tumors With Highly Targeted Alpha Radiation

Medgadget

Special software that takes DICOM images from CT scanners and creates a treatment plan, defines the distribution of the Alpha DaRT sources within the tumor. This year it is scheduled for May 16-18, 2023 in Tel Aviv, and topics range from medical robotics, to bio-convergence, to the impact of AI on biopharma.